GlassScriptPhysician profile
Tejinder S Ahuja
NPI 1144277294
$58,661.14
in general payments reported to CMS, 2019-2025
13 companies · $14K in 2025
The $14K reported for 2025 was more than what 96% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $778 · 2022: $51.34 · 2023: $287 · 2024: $28K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Travel and Lodging: $2,217 · Food and Beverage: $1,186 · Education: $39.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,365.00 |
| Travel and Lodging | $2,217.17 |
| Food and Beverage | $1,186.27 |
| Education | $39.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $23,232.85 | 2023-2025 | Jardiance |
| Lilly USA, LLC | $19,266.14 | 2024-2025 | Jardiance |
| Akebia Therapeutics INC | $14,913.35 | 2019-2024 | Vafseo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $735.00 | 2020 | |
| Horizon Therapeutics Plc | $150.87 | 2019-2020 | |
| Scpharmaceuticals INC. | $100.00 | 2025 | |
| Calliditas Therapeutics US INC. | $100.00 | 2024 | |
| Amgen INC. | $69.45 | 2024 | Tavneos |
| Aurinia Pharma U.S., INC. | $26.98 | 2022 | |
| Alexion Pharmaceuticals, INC. | $24.36 | 2022 | |
| Glaxosmithkline, LLC. | $17.61 | 2020 | |
| Travere Therapeutics, INC. | $14.94 | 2025 | Thiola |
| Biomerieux INC | $9.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tejinder Ahuja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.